Therapeutic administration of mouse mast cell protease 6 improves functional recovery after traumatic spinal cord injury in mice by promoting remyelination and reducing glial scar formation
The FASEB Journal · 2023
DOI: 10.1096/fj.202201942rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Tim Vangansewinkel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cardio and Organ Systems, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium. Hauptthemen laut MEDLINE: Remyelination, Spinal Cord Injuries. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agentschap voor Innovatie door Wetenschap en Technologie.
Abstract (Originalsprache)
Traumatic spinal cord injury (SCI) most often leads to permanent paralysis due to the inability of axons to regenerate in the adult mammalian central nervous system (CNS). In the past, we have shown that mast cells (MCs) improve the functional outcome after SCI by suppressing scar tissue formation at the lesion site via mouse mast cell protease 6 (mMCP6). In this study, we investigated whether recombinant mMCP6 can be used therapeutically to improve the functional outcome after SCI. Therefore, we applied mMCP6 locally via an intrathecal catheter in the subacute phase after a spinal cord hemisection injury in mice. Our findings showed that hind limb motor function was significantly improved in mice that received recombinant mMCP6 compared with the vehicle‐treated group. In contrast to our previous findings in mMCP6 knockout mice, the lesion size and expression levels of the scar components fibronectin, laminin, and axon‐growth‐inhibitory chondroitin sulfate proteoglycans were not affected by the treatment with recombinant mMCP6. Surprisingly, no difference in infiltration of CD4+ T cells and reactivity of Iba‐1+ microglia/macrophages at the lesion site was observed between the mMCP6‐treated mice and control mice. Additionally, local protein levels of the pro‐ and anti‐inflammatory mediators IL‐1β, IL‐2, IL‐4, IL‐6, IL‐10, TNF‐α, IFNγ, and MCP‐1 were comparable between the two treatment groups, indicating that locally applied mMCP6 did not affect inflammatory processes after injury. However, the increase in locomotor performance in mMCP6‐treated mice was accompanied by reduced demyelination and astrogliosis in the perilesional area after SCI. Consistently, we found that TNF‐α/IL‐1β‐astrocyte activation was decreased and that oligodendrocyte precursor cell (OPC) differentiation was increased after recombinant mMCP6 treatment in vitro. Mechanistically, this suggests effects of mMCP6 on reducing astrogliosis and improving (re)myelination in the spinal cord after injury. In conclusion, these data show for the first time that recombinant mMCP6 is therapeutically active in enhancing recovery after SCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardio and Organ Systems, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium.
- VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium.
- Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium.
- Department of Neuroscience, Faculty of Medicine and Life Sciences, Biomedical Research Institute, Hasselt University, Hasselt, Belgium.
- Department Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
- University MS Center (UMSC) Hasselt-Pelt, Hasselt, Belgium.
ORCID-Profile: Sven Hendrix
Förderung
- Agentschap voor Innovatie door Wetenschap en Technologie
Zitieren
APA
Vangansewinkel, T., Lemmens, S., Tiane, A., Geurts, N., Dooley, D., Vanmierlo, T., Pejler, G., & Hendrix, S. (2023). Therapeutic administration of mouse mast cell protease 6 improves functional recovery after traumatic spinal cord injury in mice by promoting remyelination and reducing glial scar formation. The FASEB Journal. https://doi.org/10.1096/fj.202201942rr
Vancouver
Vangansewinkel T, Lemmens S, Tiane A, Geurts N, Dooley D, Vanmierlo T, et al. Therapeutic administration of mouse mast cell protease 6 improves functional recovery after traumatic spinal cord injury in mice by promoting remyelination and reducing glial scar formation. The FASEB Journal. 2023. doi:10.1096/fj.202201942rr
BibTeX
@article{Vangansewinkel2023,
author = {Vangansewinkel, Tim and Lemmens, Stefanie and Tiane, Assia and Geurts, Nathalie and Dooley, Dearbhaile and Vanmierlo, Tim and Pejler, Gunnar and Hendrix, Sven},
title = {Therapeutic administration of mouse mast cell protease 6 improves functional recovery after traumatic spinal cord injury in mice by promoting remyelination and reducing glial scar formation},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202201942rr}
}
EUVIMED